Actor portrayal.
Welcome to the PURPOSE
Program Investigator Site
Thank you so much for working with us to help evaluate the safety and efficacy of investigational lenacapavir and emtricitabine/tenofovir alafenamide for PrEP.
See the Gilead statement
on global access planning for
lenacapavir for HIV prevention
What's Happening With PURPOSE 1
Results from the PURPOSE 1 clinical study are now published.
Select one of the sites to visit to see what they found.
What Are the Findings of PURPOSE 2
The outcomes from the PURPOSE 2 clinical study are now available. Select one of the sites to see what they found.
Actor portrayal.
PURPOSE Presentations and Publications
Here are some links to the presentations and publications about the PURPOSE studies.
PURPOSE 1 - clinicaltrials.gov
PURPOSE 2 - clinicaltrials.gov
PURPOSE 3 - clinicaltrials.gov
PURPOSE 4 - clinicaltrials.gov
PURPOSE 5 - clinicaltrials.gov
PURPOSE 365 - clinicaltrials.gov
Annual Persistence in Use of Twice-Yearly Lenacapavir Versus Daily Oral PrEP in the PURPOSE 1 Phase 3 Trial (Glasgow 2024)
Twice-Yearly Lenacapavir or Daily Oral Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study (IAS 2024)
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (NEJM)
Twice-Yearly Lenacapavir PrEP in Cisgender Gay, Bisexual, and Other Men, Transgender Women and Men, and Gender-Diverse People (PURPOSE 2) (Glasgow 2024)
A summary of PURPOSE 2, a study looking at how well lenacapavir works for HIV prevention in cisgender gay, bisexual, and other men, transgender people, and gender nonbinary people who have sex with partners assigned male at birth (Glasgow 2024)
Twice-Yearly Lenacapavir for HIV Prevention in Cisgender Gay, Bisexual, and Other Men, Transgender Women, Transgender Men, and Gender-Nonbinary People who Have Sex With Partners Assigned Male at Birth: Interim Analysis Results from the PURPOSE 2 Study (HIVR4P 2024)
Twice-Yearly Lenacapavir for HIV Prevention in Cisgender Gay, Bisexual, and Other Men, Transgender Women, Transgender Men, and Gender-Nonbinary People who Have Sex With Partners Assigned Male at Birth (NEJM)
Update on Lenacapavir for PrEP: Results From the Interim Analyses of PURPOSE 1 and PURPOSE 2 (IDWeek 2024)
Centering Community Leadership with PURPOSE: Inclusion of Adolescents, Cisgender Women, and Pregnant and Lactating Individuals in a Phase 3 Clinical Trial Evaluating Lenacapavir and Emtricitabine/Tenofovir Alafenamide for PrEP (AIDS 2024)
A summary of PURPOSE 2, a study looking at how well lenacapavir works for HIV prevention in cisgender gay, bisexual, and other men; transgender; and gender-nonbinary people who have sex with partners assigned male at birth (HIVR4P 2024)
Global Racial, Ethnic, and Gender Diversity Among Participants Enrolled in the PURPOSE 2 Trial of Lenacapavir for Pre-Exposure Prophylaxis (HIVR4P 2024)
Pregnant and Lactating People in the Lenacapavir for HIV PrEP PURPOSE Program
Global Consultation to Plan for Inclusion of Pregnant and Lactating Populations in a Phase 3 PrEP Clinical Trial
Inclusion, Experience, and Data: Approaches for Prioritizing the Transgender and Gender-Diverse Voice in a Phase 3 Clinical Trial of Long-Acting PrEP
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
Update on Gilead's HIV Prevention Trials presented at R4P 2021
Advancing Novel HIV Prevention Strategies, Together: A Scientific and Community Exchange presented at R4P 2021
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project
Sample size calculation for recency assay based clinical trials
Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV incidence
Community Inclusion Videos
Bringing the trial study sites to where the need is the greatest
Explore a video from Moupali Das, MD, MPH, the Executive Director of HIV Clinical Development at Gilead, as she describes why it was important that PURPOSE 2 add study sites in new locations in the country.
Video length: 1 min.
Inclusion from the start
Learn about how we think "Having everyone at the table makes the science better."
Video length: 1 min.